Erschienen in:
01.12.2015 | Original Article
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer
verfasst von:
Tatsuya Kurihara, Mari Kogo, Masakazu Ishii, Ken Shimada, Keiichiro Yoneyama, Katsuya Kitamura, Shunichi Shimizu, Hitoshi Yoshida, Yuji Kiuchi
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 6/2015
Einloggen, um Zugang zu erhalten
Abstract
Purpose
We conducted a retrospective cohort study to examine whether neutropenia could be an indicator of good prognosis in patients treated with gemcitabine (GEM) for unresectable pancreatic cancer.
Methods
A total of 178 patients with unresectable pancreatic cancer, who were treated with first-line (n = 121) or second-line (n = 57) GEM, were included in our analyses. A Cox proportional hazard model was used to examine the effect of the grade of GEM-induced neutropenia on prognosis. Furthermore, the difference in survival time for each grade was assessed using a log-rank test.
Results
In the first-line population, the hazard ratios of patients with grade 2 or grade 3 neutropenia compared with the ratios of those without neutropenia (grade 0) were 0.43 (95% CI 0.27–0.70) and 0.37 (0.21–0.65), respectively (p < 0.05). The median survival time (MST) was 3.8 months for grade 0, 9.4 months for grade 2, and 10.1 for grade 3. Landmark analysis of the second-line population revealed a hazard ratio of 0.52 (0.30–0.82) for grade 1 and 0.49 for grade 2 (0.28–0.72) (p < 0.05). MST was 1.3 months for grade 0, 4.7 months for grade 1, and 4.6 months for grade 2.
Conclusions
We found that neutropenia grade was an indicator of good prognosis in patients treated with first-line and second-line GEM for unresectable pancreatic cancer. A prospective study should be performed to examine whether dosage adjustment using neutropenia grade as an indicator would improve prognosis.